ARVN Latest Press Releases

-- November 11, 2026 --

Arvinas to Present at Jefferies Global Healthcare Conference Globe Newswire 7:00 AM

-- November 4, 2026 --

Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH) Annual Meeting Globe Newswire 4:01 PM

-- November 3, 2026 --

Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 7:00 AM

-- October 27, 2026 --

Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation Globe Newswire 4:01 PM

Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 Globe Newswire 7:00 AM

-- October 7, 2026 --

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease Globe Newswire 7:00 AM

-- October 1, 2026 --

Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders Globe Newswire 4:01 PM

-- September 29, 2026 --

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- September 28, 2026 --

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate Globe Newswire 7:00 AM

-- September 3, 2026 --

Arvinas to Participate in Upcoming Investor Conferences Globe Newswire 4:06 PM

-- September 1, 2026 --

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- August 4, 2026 --

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 7:00 AM

-- July 28, 2026 --

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026 Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes